BioSpace News Archive

Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure.

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent business highlights.

Alvotech Holdings S.A. announced today that the extraordinary general meeting of shareholders of OACB (the “Extraordinary General Meeting”) to approve the pending business combination (the “Business Combination”) between Alvotech S.A., Alvotech (“TopCo”) and OACB is scheduled to be held on Tuesday, June 7, 2022 at 10:00 a.m. Eastern time.

A new National Institutes of Health -funded study found that pregnant women had been exposed to rising levels of certain chemicals, especially replacement chemicals: chemicals meant to replace other chemicals that have been banned or phased out.

Vallon Pharmaceuticals, Inc. today announced that the Japan Patent Office has granted Patent No. 7054709 titled, “ Abuse Deterrent Formulations of Amphetamine ,” covering ADAIR 1 , the Company’s proprietary buse-deterrent formulation of immediate-release dextroamphetamine.

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today issued a Letter to Shareholders providing highlights on the Company’s recent developments and updates.

Neuvivo, a biopharmaceutical company dedicated to delivering an effective, safe ALS treatment to patients, today announced that it has initiated cGMP manufacturing of NP001 for the treatment of ALS ( Lou Gehrig’s Disease).

Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies for metabolic and chronic conditions, today reported the completion of a Phase 1 trial for its lead clinical-stage program, GLY-200, as a treatment for type 2 diabetes (T2D).

Valencia Technologies Corporation (" Valencia " or the “Company”), a privately held company, today announced it has retained PRIA Healthcare to assist in patient access for Valencia’s recently FDA approved proprietary product, eCoin®.

Telememory Holding Corp., the makers of MoodSpark, has purchased Dthera Sciences, a pioneer in the digital therapeutics industry and leader in developing innovative quality of life therapies for those suffering from cognitive decline.